Striking dichotomy in outcome ofMYCN-amplified neuroblastoma in the contemporary era
Author:
Affiliation:
1. Department of Pediatrics; Memorial Sloan-Kettering Cancer Center; New York New York
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference47 articles.
1. Long-term survival of children with neuroblastoma prior to the neuroblastoma screening project in Germany;Burkhardt-Hammer;Med Pediatr Oncol.,2002
2. Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study;Schroeder;Br J Cancer.,2009
3. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry;Haupt;J Clin Oncol.,2010
4. Outcome of high-risk neuroblastoma using a dose-intensity approach: improvement in initial but not in long-term results;Castel;Med Pediatr Oncol.,2001
5. Intensified chemotherapy increases survival rates of patients with stage 4 neuroblastoma with MYCN amplification;Kaneko;J Pediatr Hematol Oncol.,2002
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy;Cancers;2024-04-29
2. Incidence and survival for childhood cancer by endorsed non‐stage prognostic indicators in Australia;Pediatric Blood & Cancer;2024-01-24
3. Predictive value of 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography/computed tomography parameters for MYCN amplification in high-risk neuroblastoma;European Journal of Radiology;2024-01
4. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes;Cancers;2023-10-03
5. Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report;Cancers;2023-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3